JP6976859B2 - ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療 - Google Patents

ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療 Download PDF

Info

Publication number
JP6976859B2
JP6976859B2 JP2017559025A JP2017559025A JP6976859B2 JP 6976859 B2 JP6976859 B2 JP 6976859B2 JP 2017559025 A JP2017559025 A JP 2017559025A JP 2017559025 A JP2017559025 A JP 2017559025A JP 6976859 B2 JP6976859 B2 JP 6976859B2
Authority
JP
Japan
Prior art keywords
subject
certain embodiments
actriib
seq
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017559025A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018520094A (ja
JP2018520094A5 (cg-RX-API-DMAC7.html
Inventor
エム．アティエ ケネス
ラアデム アブデラーマン
チョプラ ラジェシュ
バックストロム ジェイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2018520094A publication Critical patent/JP2018520094A/ja
Publication of JP2018520094A5 publication Critical patent/JP2018520094A5/ja
Priority to JP2021131870A priority Critical patent/JP2021191755A/ja
Application granted granted Critical
Publication of JP6976859B2 publication Critical patent/JP6976859B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017559025A 2015-05-13 2016-05-12 ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療 Expired - Fee Related JP6976859B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021131870A JP2021191755A (ja) 2015-05-13 2021-08-13 ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562161136P 2015-05-13 2015-05-13
US62/161,136 2015-05-13
US201562173836P 2015-06-10 2015-06-10
US62/173,836 2015-06-10
US201562243457P 2015-10-19 2015-10-19
US62/243,457 2015-10-19
PCT/US2016/031999 WO2016183280A1 (en) 2015-05-13 2016-05-12 Treatment of beta-thalassemia using actrii ligand traps

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021131870A Division JP2021191755A (ja) 2015-05-13 2021-08-13 ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療

Publications (3)

Publication Number Publication Date
JP2018520094A JP2018520094A (ja) 2018-07-26
JP2018520094A5 JP2018520094A5 (cg-RX-API-DMAC7.html) 2019-06-20
JP6976859B2 true JP6976859B2 (ja) 2021-12-08

Family

ID=57248528

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017559025A Expired - Fee Related JP6976859B2 (ja) 2015-05-13 2016-05-12 ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療
JP2021131870A Pending JP2021191755A (ja) 2015-05-13 2021-08-13 ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021131870A Pending JP2021191755A (ja) 2015-05-13 2021-08-13 ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療

Country Status (15)

Country Link
US (1) US20180125928A1 (cg-RX-API-DMAC7.html)
EP (1) EP3294320A4 (cg-RX-API-DMAC7.html)
JP (2) JP6976859B2 (cg-RX-API-DMAC7.html)
KR (1) KR102640198B1 (cg-RX-API-DMAC7.html)
CN (1) CN107847562A (cg-RX-API-DMAC7.html)
AU (2) AU2016261913B2 (cg-RX-API-DMAC7.html)
CA (1) CA2985777A1 (cg-RX-API-DMAC7.html)
HK (1) HK1251157A1 (cg-RX-API-DMAC7.html)
IL (2) IL284686B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20160092B1 (cg-RX-API-DMAC7.html)
MY (1) MY189601A (cg-RX-API-DMAC7.html)
PH (1) PH12017502079A1 (cg-RX-API-DMAC7.html)
TN (1) TN2017000468A1 (cg-RX-API-DMAC7.html)
TW (2) TWI814187B (cg-RX-API-DMAC7.html)
WO (1) WO2016183280A1 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612041B2 (en) 2005-11-23 2009-11-03 Acceleron Pharma Inc. Isolated activin-binding ActRIIa polypeptide comprising the SEQ ID NO: 7 and uses for promoting bone growth
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
US8058229B2 (en) 2008-08-14 2011-11-15 Acceleron Pharma Inc. Method of increasing red blood cell levels or treating anemia in a patient
CN102482339B (zh) 2009-06-08 2015-06-17 阿塞勒隆制药公司 用于增加产热脂肪细胞的方法
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
US8710016B2 (en) 2009-11-17 2014-04-29 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
AU2013337677B2 (en) 2012-11-02 2018-06-28 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
BR122023023170A2 (pt) 2014-06-13 2024-02-20 Acceleron Pharma Inc. Uso de um antagonista de actrii no tratamento ou prevenção de úlcera cutânea associada com beta-talassemia
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
CN107533040B (zh) 2014-12-03 2022-03-29 细胞基因公司 激活素-actrii拮抗剂及用于治疗贫血症的用途
JP2018522579A (ja) 2015-05-20 2018-08-16 セルジーン コーポレイション アクチビンＩＩ型受容体リガンドトラップを使用するβ−サラセミアのインビトロ細胞培養法
EP3370754A4 (en) 2015-11-04 2019-10-23 Acceleron Pharma Inc. METHOD FOR INCREASING ERYTHROCYTE CONCENTRATION AND TREATMENT OF INEFFICIENT ERYTHROPOIESE
WO2017091706A1 (en) 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders
US10722558B2 (en) * 2016-07-15 2020-07-28 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
EA201990226A1 (ru) 2016-07-27 2019-08-30 Акселерон Фарма Инк. Способы и композиции для лечения миелофиброза
US11013785B2 (en) 2016-11-10 2021-05-25 Keros Therapeutics, Inc. Activin receptor type IIA variants and methods of use thereof
DK3638243T3 (da) * 2017-06-14 2024-10-28 Celgene Corp Fremgangsmåder til behandling af myeloproliferativ neoplasma-forbundet myelofibrose og anæmi
KR20200085832A (ko) 2017-11-09 2020-07-15 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
CN120535607A (zh) 2018-01-12 2025-08-26 科乐斯疗法公司 激活素受体iib型变体及其使用方法
EP3788065B1 (en) 2018-04-30 2025-08-27 The Children's Hospital Of Philadelphia Improving anemias by combining agents
AU2019266314B2 (en) 2018-05-09 2025-05-15 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
KR20210088548A (ko) * 2018-10-31 2021-07-14 셀진 코포레이션 액티빈-actrii 리간드 트랩을 사용하는 고리 철적혈모구가 있는 대상체에서 매우 낮은, 낮은 또는 중간 위험 골수이형성 증후군으로 인한 빈혈의 치료
MX2022000782A (es) 2019-07-19 2022-04-18 Vifor Int Ag Inhibidores de la ferroportina para el uso en el tratamiento de la beta-talasemia dependiente de transfusiones (tdt).
CN112924684B (zh) * 2019-12-05 2022-07-29 中国科学院大连化学物理研究所 用于区分抑郁症和非抑郁症的生物标志物和包括其的诊断试剂盒
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
BR112022020628A2 (pt) * 2020-04-13 2022-11-29 Celgene Corp Métodos para tratamento de anemia usando uma armadilha de ligante de actriib e fedratinibe
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof
EP4240399A4 (en) * 2020-11-06 2024-10-09 Acceleron Pharma Inc. FORMULATIONS WITH ACTRII POLYPEPTIDE VARIANTS
US20240181007A1 (en) * 2021-01-08 2024-06-06 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
CA3205845A1 (en) 2021-01-20 2022-07-28 Francesca VINCHI Ferroportin-inhibitors for the use in the treatment of myelodysplastic syndromes (mds)
WO2025003139A1 (en) 2023-06-26 2025-01-02 Vifor (International) Ag Ferroportin-inhibitors for the use in the treatment of hereditary haemochromatosis (hh)
WO2025122830A1 (en) * 2023-12-08 2025-06-12 Keros Therapeutics, Inc. Methods of using activin receptor type ii signaling inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4247A (en) * 1845-11-01 Jordan l
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
EP2468290B1 (en) * 2006-12-18 2015-04-01 Acceleron Pharma, Inc. Activin-ActRII Antagonists for use in treating anemia
US20100015144A1 (en) * 2008-06-26 2010-01-21 Acceleron Pharma Inc. Methods for dosing an activin-actriia antagonist and monitoring of treated patients
US8058229B2 (en) * 2008-08-14 2011-11-15 Acceleron Pharma Inc. Method of increasing red blood cell levels or treating anemia in a patient
MX340451B (es) * 2009-09-09 2016-07-08 Acceleron Pharma Inc Antagonistas de actriib y dosificacion y usos de los mismos.
DK3520805T3 (da) * 2011-10-17 2021-04-19 Acceleron Pharma Inc Sammensætninger til behandling af myelofibrose
EP2830642B1 (en) * 2012-03-30 2019-08-28 Shire Human Genetic Therapies, Inc. Subcutaneous administration of iduronate- 2-sulfatase
WO2014066486A2 (en) * 2012-10-24 2014-05-01 Celgene Corporation Biomarker for use in treating anemia
US20150266950A1 (en) * 2012-10-24 2015-09-24 Celgene Corporation Methods for treating anemia
MX361412B (es) * 2012-11-27 2018-12-05 Childrens Medical Center Direccion de elementos reguladores distales de bcl11a para reinduccion de hemoglobina fetal.

Also Published As

Publication number Publication date
TN2017000468A1 (en) 2019-04-12
JP2018520094A (ja) 2018-07-26
IL284686B (en) 2023-01-01
WO2016183280A1 (en) 2016-11-17
AU2016261913A1 (en) 2017-11-30
AU2021258087A1 (en) 2021-11-25
CN107847562A (zh) 2018-03-27
MY189601A (en) 2022-02-18
HK1251157A1 (zh) 2019-01-25
IL284686B2 (en) 2023-05-01
KR102640198B1 (ko) 2024-02-23
IL284686A (en) 2021-08-31
PH12017502079A1 (en) 2018-06-11
TW201709927A (zh) 2017-03-16
AU2016261913B2 (en) 2021-08-12
US20180125928A1 (en) 2018-05-10
TW202231294A (zh) 2022-08-16
NZ737043A (en) 2025-02-28
JOP20160092B1 (ar) 2023-03-28
TWI814187B (zh) 2023-09-01
EP3294320A1 (en) 2018-03-21
CA2985777A1 (en) 2016-11-17
IL255527A (en) 2018-01-31
TWI762444B (zh) 2022-05-01
JP2021191755A (ja) 2021-12-16
EP3294320A4 (en) 2018-12-26
KR20180006437A (ko) 2018-01-17
AU2021258087B2 (en) 2023-04-27
IL255527B (en) 2021-07-29

Similar Documents

Publication Publication Date Title
JP6976859B2 (ja) ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療
JP6714646B2 (ja) アクチビン−ＡｃｔＲＩＩアンタゴニスト並びに骨障害及び他の障害の治療に対する使用
JP7496686B2 (ja) 骨髄増殖性腫瘍関連骨髄線維症及び貧血を治療するための方法
AU2015358469B2 (en) Activin-ActRII antagonists and uses for treating anemia
US20230142386A1 (en) Activin-actrii antagonists and uses for treating anemia
HK1254086B (en) Activin-actrii antagonists and uses for treating bone and other disorders
NZ747422B2 (en) Activin-actrii antagonists and uses for treating bone and other disorders
HK1214525B (en) Activin-actrii antagonists and uses for treating bone and other disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180301

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190510

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190510

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200331

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210816

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211019

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211110

R150 Certificate of patent or registration of utility model

Ref document number: 6976859

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees